Biomark Diagnostics Inc
20B
Company Profile
Business description
Biomark Diagnostics Inc is developing its early-stage cancer diagnostic technology platform. It is cancer diagnostics technology platform leverages "Omics" and machine learning with a focus on how to detect and treat cancers. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.
Contact
10451 Shellbridge Way
Suite 145
RichmondBCV6X 2W8
CANSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 March 2027
Employees
Stocks News & Analysis
stocks
A better way to predict long-term stock returns
A value-weighted version of the CAPE ratio corrects a structural flaw and delivers stronger forecasts of long-term stock returns.
stocks
Five star stock added to August best ideas list
Morningstar analysts hand pick this undervalued opportunity for their August global best ideas.
stocks
Undervalued supermarket share sees sales improvement
Improving sales trends but recovery remains gradual.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,923.90 | 3.70 | 0.04% |
| CAC 40 | 8,118.60 | 61.17 | -0.75% |
| DAX 40 | 25,401.37 | 167.19 | -0.65% |
| Dow JONES (US) | 52,573.29 | 509.19 | 0.98% |
| FTSE 100 | 10,706.81 | 56.37 | 0.53% |
| HKSE | 24,917.60 | 111.97 | 0.45% |
| NASDAQ | 26,333.04 | 251.31 | 0.96% |
| Nikkei 225 | 63,492.99 | 518.35 | -0.81% |
| NZX 50 Index | 13,560.69 | 19.64 | -0.14% |
| S&P 500 | 7,656.98 | 65.28 | 0.86% |
| S&P/ASX 200 | 8,749.90 | 8.70 | 0.10% |
| SSE Composite Index | 3,885.33 | 2.78 | -0.07% |